Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10604-10616

  Marín Aguilera, Mercedes ^a   Reig, Òscar ^a,b   Lozano, Juan José ^b   Jiménez, Natalia ^a   García Recio, Susana ^a,c   Erill, Nadina ^d   Gaba, Lydia ^b   Tagliapietra, Andrea ^b   Ortega, Vanesa ^b   Carrera, Gemma ^e   Colomer, Anna ^d   Gascón, Pedro ^c   Mellado, Begoña ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Translational Research Laboratory   (Spain)

^d Althia Advanced Laboratories of Translational Health   (Spain)

^e HOSPITAL PLATÓ   (Spain)

Author keywords

Cell search system; Circulating tumor cells; Microarrays; Peripheral blood

Indexed keywords

ABC TRANSPORTER A13; GELATINASE B; NEUTROPHIL COLLAGENASE; TRANSCRIPTION FACTOR ERG;

ABCA13 GENE; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CEACAM1 GENE; CELL COUNT; CELL DEATH; CELL GROWTH; CELL MOTION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CRISP3 GENE; ERG GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ANALYSIS; HP GENE; HPR GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METABOLISM; MMP8 GENE; MMP9 GENE; OLFM4 GENE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SELENBP1 GENE; SIGNAL TRANSDUCTION; BLOOD; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR EMBOLISM;

ADULT; AGED; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS;

EID: 84929576366     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3550     Document Type: Article

References (36)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-E386.
2. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91: 1113-1124.
3. Danila DC, Pantel K, Fleisher M, Scher HI. Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J. 2011; 17: 438-450.
4. Miller MC, Doyle GV, Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol. 2010; 2010: 617421.
5. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13: 920-928.
6. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14: 6302-6309.
7. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2: 25ra23.
8. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009; 69: 2912-2918.
9. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13: 2023-2029.
10. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009; 15: 2091-2097.
11. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10: 233-239.
12. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006; 127: 679-695.
13. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012; 13: 1105-1113.
14. Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 2012; 13: 1114-1124.
15. Mellado B, Del C, V, Colomer D, Gutierrez L, Castel T, Quinto L et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol. 2002; 20: 4032-4039.
16. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18: 11-22.
17. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3: 453-458.
18. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11: 85-95.
19. Thomassen M, Tan Q, Kruse TA. Gene expression metaanalysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer. 2008; 8: 394.
20. Dahlman A, Edsjo A, Hallden C, Persson JL, Fine SW, Lilja H et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. Prostate Cancer Prostatic Dis. 2010; 13: 369-375.
21. Rucci N, Sanita P, Angelucci A. Roles of metalloproteases in metastatic niche. Curr Mol Med. 2011; 11: 609-622.
22. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008; 10: 177-188.
23. Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernandez PL, Bermudo R, Buxo E et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012; 11: 329-339.
24. Yu L, Wang L, Chen S. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Neoplasma. 2011; 58: 9-13.
25. Yang M, Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res. 1998; 58: 3150-3153.
26. Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene. 2006; 25: 4965-4974.
27. Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer. 2012; 118: 3208-3221.
28. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
29. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10: 6897-6904.
30. Department of Biostatistics and Computational Biology.Dana-Farber Cancer Institute and Harvard School of Public Health . 2012. Ref Type: Electronic Citation
31. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31: e15.
32. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33: e175.
33. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98: 5116-5121.
34. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de BB et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 2009; 37: D619-D622.
35. Venables WN, Ripley BD. Modern applied statistics with S, 4th ed. New York: 2002.
36. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.